What new Cosentyx (secukinumab) indications were approved from 2024 onward?
I can’t give an accurate list of Cosentyx indication approvals for 2024, 2025, and 2026 based on the information provided here. Drug approvals and label expansions are specific to country/region (for example, FDA in the U.S. versus EMA in the EU), and the exact dates and indication wording matter.
If you tell me the regulator and region you care about (FDA/EMA/UK MHRA/Canada/other) and whether you mean approvals only (not also updates like safety-label changes), I can format a clean year-by-year timeline for 2024–2026.
Which regulators should be checked for 2024–2026 Cosentyx label expansions?
Common places to verify new indications and label updates are:
- FDA (U.S.) label changes and “supplement approval” announcements
- EMA (Europe) extension-of-indication decisions and EPAR updates
- National regulators (UK MHRA, Health Canada, etc.)
How do you know it’s a true “new indication” versus a label clarification?
When scanning label updates, watch for wording changes that:
- Add a new disease/setting/population (for example, a new age group, line of therapy, or disease subtype).
- Change treatment for a specific population (for example, “active psoriatic arthritis” to a new subgroup).
- Add combination-use language (with other drugs) or updated criteria for use.
Not every label update is an “indication expansion.” Some are safety wording revisions, dosing adjustments, or administrative changes.
Can you share the specific Cosentyx indications you already know, so I can complete the 2024–2026 list?
If you paste any partial info you already have (for example, “Cosentyx got approval for X in 2024”), I can help you reconcile it and fill in the missing parts, keeping the timeline tight and accurate.
If you’re also tracking patents around indication expansion, where to look
If your goal is commercial strategy around label expansion, DrugPatentWatch can help track related patent landscape changes and exclusivity context. Use it here: https://www.drugpatentwatch.com/ (link provided for your reference).
---
Sources
No sources were cited because no approval/label-expansion data for 2024–2026 was provided in the prompt.